← FDA Medical Device Classifications

Fluorescence In Situ Hybridization, Topoisomerase Ii Alpha, Gene Amplification And Deletion

NXG · Class III — High Risk (PMA approval required, life-sustaining) · Unknown

Classification

FDA Product Code
NXG
Device class
Class III — High Risk (PMA approval required, life-sustaining)
Regulation
Review panel
PA
Medical specialty
Unknown
Submission type
2
GMP exempt
N
Life sustaining
N
Implant
N
Third-party review
N

Definition

Topoisomerase ii alpha (top2a) fluorescence in situ hybridization (fish) kit is to detect the top2a gene copy number changes (amplification and deletion) in breast cancer using formalin-fixed, paraffin-embeded human breast cancer tissue specimen.

Market data

Cleared 510(k) submissions
0
Registered establishments
0

Source

Authoritative
FDA Device Classification database
Machine
JSON-LD · Markdown